AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$RMD

Farrell Michael J. sold $1.1M of RMD

Farrell Michael J. (Chairman and CEO) sold 4,991 shares of RESMED INC (RMD) at $222.44 ($1.11M total) on 2026-09-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Farrell Michael J.
Published Sep 10, 2026, 10:40 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 11:09 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RMD
Bearish
medium confidence
Mentioned
$RMD
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RMDBearishLow
01

Why it matters

A $1.1M sale by the CEO may prompt short sellers to add positions, but the amount is not material for a $10B‑plus market cap.

02

Market read

Primary disclosure of an insider sale; modest materiality but relevant for short‑term traders.

03

What to watch

Potential upcoming earnings or strategic announcements that prompted the pre‑planned sale.

Relevance 5/10Novelty 6/10Timing: transaction dated 2026-09-08

Background

Form 4 filing discloses insider trades; investors monitor such filings for signals.

Company-level read

Ticker impact

$RMDBearishMedium confidence
Context

CEO Michael J. Farrell sold 4,991 shares for $1.1M via a 10b5‑1 plan on 2026‑09‑08.

Expected impact

Potential short‑term downward pressure on RMD stock.

Evidence & confidence

The sale size ($1.1M) is modest for a large cap, but the insider's role heightens relevance.

Market effects

Sector

Limited; medical device sector unlikely to be broadly affected.

Regional

None beyond U.S. equity markets.

Global

Low; isolated insider transaction.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to company outlook.

Key entities

  • Company
    ResMed Inc.

    Medical device manufacturer listed on NYSE under ticker RMD.

  • Executive
    Michael J. Farrell

    Chairman and CEO of ResMed.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RMD insider trading history →

Related articles

$RMDMedAI 8/10

What Sent ResMed Stock Lower?

ResMed (RMD) shares dropped 9.1% on October 30, 2026, following its fiscal Q1 2027 earnings release. The company beat earnings and revenue estimates, with EPS of $2.91 and revenue of $1.41B. Despite 14% higher EPS YoY, revenue growth slowed to 5.9%. Peers also fell, with Stryker (SYK) down 6.4% after missing estimates. The broader market declined due to AI sector selloff. ResMed's stock is down 8.4% over the past year.

finance.yahoo.com
$RMDMed

ResMed (RMD) Q1 2027 Earnings Call Transcript

ResMed (RMD) reported Q1 2027 earnings, highlighting innovation in sleep health products, including new bilevel devices and fabric masks. The company saw a 6% increase in therapy adherence with fabric masks and 4.3% with AI-driven Smart Comfort. ResMed also improved gross margins and expanded U.S. manufacturing. The myAir app, with 13M+ downloads, enhances patient engagement and compliance.

finance.yahoo.com
$RMDMedAI 8/10

What ResMed (RMD) Said on Its Q1 Earnings Call

ResMed (RMD) reported Q1 residential care software revenue declined 7% but increased 5% on a constant-currency basis. The company launched new devices and digital tools, with management highlighting growth in patient engagement. Non-GAAP gross margin rose to 62.5%. ResMed maintained its fiscal 2027 guidance, expecting 5-7% core revenue growth and EPS of $12-$12.25. The company is expanding U.S. manufacturing and discontinuing Astral ventilators.

finance.yahoo.com
$RMDHighAI 8/10

ResMed 3Q 2026: Revenue $1.41B, EPS $2.92— 10-Q Summary

ResMed reported 3Q 2026 revenue of $1.41B, up 5.9% YoY, with net income rising 20% to $418.41M and EPS increasing 23.2% to $2.92. Sleep and Breathing Health revenue grew 8%, while Residential software revenue declined 7% post-MatrixCare sale. The company completed the MatrixCare divestiture and expects input-cost inflation to persist through fiscal 2027.

tradingview.com